Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NSPR
stocks logo

NSPR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.62M
+34.5%
-0.200
+11.11%
2.36M
+54.45%
-0.205
-6.82%
3.17M
+78.52%
-0.210
-19.23%
Estimates Revision
The market is revising Upward the revenue expectations for InspireMD, Inc. (NSPR) for FY2025, with the revenue forecasts being adjusted by 1.64% over the past three months. During the same period, the stock price has changed by -20.66%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.64%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.32%
In Past 3 Month
Stock Price
Go Down
down Image
-20.66%
In Past 3 Month
Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.920
sliders
Low
5.00
Averages
5.00
High
5.00
Current: 1.920
sliders
Low
5.00
Averages
5.00
High
5.00
Piper Sandler
Overweight
downgrade
$4
2025-05-12
Reason
Piper Sandler
Price Target
$4
2025-05-12
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on InspireMD to $4 from $4.50 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results with sales above its expectations. The company pushed out expectations for FDA approval for its CGuard Prime stent to Q3 2025 from the first half of 2025 due to circumstances beyond the company's control. There was also a slight wiggle to expected U.S. launch timelines for the company's SwitchGuard TCAR system in development to late 2026, Piper adds.
Lake Street
Frank Takkinen
Strong Buy
Initiates
$5
2024-12-11
Reason
Lake Street
Frank Takkinen
Price Target
$5
2024-12-11
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for InspireMD Inc (NSPR.O) is -2.37, compared to its 5-year average forward P/E of -2.12. For a more detailed relative valuation and DCF analysis to assess InspireMD Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.12
Current PE
-2.37
Overvalued PE
-0.53
Undervalued PE
-3.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.41
Undervalued EV/EBITDA
-1.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.32
Current PS
0.00
Overvalued PS
10.69
Undervalued PS
1.96
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NSPR News & Events

Events Timeline

(ET)
2025-12-03
08:20:00
BioCardia Appoints Marvin Slosman to Board of Directors
select
2025-11-24 (ET)
2025-11-24
07:44:16
InspireMD Reveals CREST-2 Data Publication in NEJM
select
2025-11-21 (ET)
2025-11-21
09:02:52
InspireMD Announces Inducement Grants in Compliance with Nasdaq Listing Regulations
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-24Newsfilter
InspireMD Publishes Positive CREST-2 Data Confirming Efficacy of Carotid Stenting
  • CREST-2 Study Results: InspireMD presented CREST-2 data at the SVIN Annual Meeting on November 21, 2025, showing that carotid artery stenting (CAS) significantly outperformed intensive medical management for patients with asymptomatic carotid stenosis. This finding provides crucial clinical evidence that could reshape treatment protocols for carotid disease.
  • Clinical Trial Scale: The CREST-2 trial, independently conducted and NIH-sponsored, involved 155 centers globally with 1,245 patients randomized to the stenting group. Results indicated a significantly reduced risk of perioperative stroke or death over four years, underscoring the efficacy of stenting.
  • Innovative Technology Advantage: InspireMD's CGuard®Prime stent demonstrated a record-low 1.93% major adverse event rate in the C-GUARDIANS trial, particularly among high-risk patients. This low event rate, combined with the positive CREST-2 results, reinforces the company's leadership in the carotid stenting market.
  • Market Outlook: CEO Marvin Slosman stated that CREST-2 validates the superiority of combining stenting with medical management, indicating a shift towards an endovascular-first approach in vascular disease treatment. With growing recognition of effective treatments for asymptomatic carotid disease, InspireMD is poised for increased market share.
[object Object]
Preview
1.0
11-20Newsfilter
InspireMD to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler

  • Company Announcement: InspireMD, Inc. will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on December 3rd, 2025, at 12:30 pm ET.

  • Webcast Availability: A live audio webcast and replay of the discussion will be accessible on the company's website under the "Investor Calendar" section.

  • Product Focus: InspireMD is focused on its CGuard® Prime carotid stent system, which aims to prevent strokes using its proprietary MicroNet™ mesh technology.

  • Investor Information: InspireMD's common stock is traded on Nasdaq under the ticker symbol NSPR, and the company provides important updates for investors on its website.

[object Object]
Preview
9.5
11-04NASDAQ.COM
InspireMD, Inc. Reports Wider Q3 Loss, Yet Surpasses Expectations

  • Earnings Report: InspireMD, Inc. reported a third-quarter loss of $12.71 million, or $0.17 per share, which is an increase from last year's loss of $7.89 million, or $0.16 per share.

  • Analyst Expectations: The company's loss was better than analysts' expectations, who had predicted a loss of $0.19 per share.

  • Revenue Growth: Revenue for the quarter rose by 39.2% to $2.52 million, up from $1.81 million in the same period last year.

  • Earnings Summary: Key figures include a loss of $12.71 million, an EPS of -$0.17, and revenue of $2.52 million compared to last year's figures.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is InspireMD Inc (NSPR) stock price today?

The current price of NSPR is 1.92 USD — it has increased 0.52 % in the last trading day.

arrow icon

What is InspireMD Inc (NSPR)'s business?

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

arrow icon

What is the price predicton of NSPR Stock?

Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is InspireMD Inc (NSPR)'s revenue for the last quarter?

InspireMD Inc revenue for the last quarter amounts to 2.52M USD, increased 39.39 % YoY.

arrow icon

What is InspireMD Inc (NSPR)'s earnings per share (EPS) for the last quarter?

InspireMD Inc. EPS for the last quarter amounts to -0.17 USD, increased 6.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for InspireMD Inc (NSPR)'s fundamentals?

The market is revising Upward the revenue expectations for InspireMD, Inc. (NSPR) for FY2025, with the revenue forecasts being adjusted by 1.64% over the past three months. During the same period, the stock price has changed by -20.66%.
arrow icon

How many employees does InspireMD Inc (NSPR). have?

InspireMD Inc (NSPR) has 85 emplpoyees as of December 05 2025.

arrow icon

What is InspireMD Inc (NSPR) market cap?

Today NSPR has the market capitalization of 81.35M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free